Advertisement
Advertisement
U.S. markets open in 9 hours 19 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Emergent BioSolutions Inc. (EBS)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
31.04+0.51 (+1.67%)
At close: 04:00PM EDT
30.66 -0.38 (-1.22%)
After hours: 04:27PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close30.53
Open30.40
Bid29.49 x 1100
Ask32.44 x 1000
Day's Range30.11 - 31.81
52 Week Range26.85 - 68.03
Volume545,932
Avg. Volume762,703
Market Cap1.56B
Beta (5Y Monthly)0.98
PE Ratio (TTM)11.13
EPS (TTM)2.79
Earnings DateJul 27, 2022 - Aug 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
117% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for EBS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Emergent Biosolutions, Inc.
    Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides EBS with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,500 employees.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
Advertisement
Advertisement